A small-scale experiment of using phage-based probiotic dietary supplement for prevention of E. coli traveler's diarrhea.

Bacteriophage Pub Date : 2015-07-24 eCollection Date: 2015-07-01 DOI:10.1080/21597081.2015.1074329

A V Aleshkin, E O Rubalskii, N V Volozhantsev, V V Verevkin, E A Svetoch, I A Kiseleva, S S Bochkareva, O Yu Borisova, A V Popova, A G Bogun, S S Afanas'ev

{"title":"A small-scale experiment of using phage-based probiotic dietary supplement for prevention of E. coli traveler's diarrhea.","authors":"A V Aleshkin, E O Rubalskii, N V Volozhantsev, V V Verevkin, E A Svetoch, I A Kiseleva, S S Bochkareva, O Yu Borisova, A V Popova, A G Bogun, S S Afanas'ev","doi":"10.1080/21597081.2015.1074329","DOIUrl":null,"url":null,"abstract":"Traveler's diarrhea (TD) is caused by Escherichia coli in 30% of cases. We have developed a phage cocktail for prophylaxis of TD caused by E.coli, Shigella flexneri, Shigella sonnei, Salmonella enterica, Listeria monocytogenes or Staphylococcus aureus, and investigated its effectiveness against infection caused by the non-pathogenic Lac (-) strain of E.coli K12 C600 in animal and human trials. On the 6th day of both animal and human trials E. coli K12 C600 strain was detected in titer of 104 CFU/g of mice feces and 106 CFU/g of human feces in the control (untreated) groups, while it was not detected in the samples of either of the study (phage-treated) groups. These results have great significance because the original coliphages included in the cocktail have a broad host-range including ETEC, EAEC and EHEC strains which cause severe cases of TD.","PeriodicalId":8686,"journal":{"name":"Bacteriophage","volume":"5 3","pages":"e1074329"},"PeriodicalIF":0.0000,"publicationDate":"2015-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21597081.2015.1074329","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bacteriophage","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21597081.2015.1074329","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/7/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 10

Abstract

Traveler's diarrhea (TD) is caused by Escherichia coli in 30% of cases. We have developed a phage cocktail for prophylaxis of TD caused by E.coli, Shigella flexneri, Shigella sonnei, Salmonella enterica, Listeria monocytogenes or Staphylococcus aureus, and investigated its effectiveness against infection caused by the non-pathogenic Lac (-) strain of E.coli K12 C600 in animal and human trials. On the 6th day of both animal and human trials E. coli K12 C600 strain was detected in titer of 10⁴ CFU/g of mice feces and 10⁶ CFU/g of human feces in the control (untreated) groups, while it was not detected in the samples of either of the study (phage-treated) groups. These results have great significance because the original coliphages included in the cocktail have a broad host-range including ETEC, EAEC and EHEC strains which cause severe cases of TD.

查看原文本刊更多论文

基于噬菌体的益生菌膳食补充剂预防大肠杆菌旅行者腹泻的小规模实验。

旅行者腹泻(TD)在30%的病例中由大肠杆菌引起。我们开发了一种噬菌体鸡尾酒，用于预防大肠杆菌、福氏志贺氏菌、索尼氏志贺氏菌、肠炎沙门氏菌、单核细胞增李斯特菌或金黄色葡萄球菌引起的TD，并在动物和人体试验中研究了其对非致病性大肠杆菌K12 C600 Lac(-)菌株感染的有效性。在动物试验和人体试验的第6天，在对照组(未处理组)小鼠粪便中检测到大肠杆菌K12 C600株滴度为104 CFU/g，在对照组(未处理组)人类粪便中检测到106 CFU/g，而在研究组(噬菌体处理组)样品中均未检测到该菌株。这些结果具有重要意义，因为鸡尾酒中包含的原始噬菌体具有广泛的宿主范围，包括导致严重TD病例的ETEC, EAEC和EHEC菌株。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bacteriophage

自引率

0.00%

发文量